Liu Tu-Chen, Shih Chia-Ju, Chiou Ya-Ling
Department of Chest Medicine, Cheng-Ching General Hospital, Taichung, Republic of China.
Department of Nutrition (Master Program), Hungkuang University, Taichung, Taiwan, Republic of China.
Food Nutr Res. 2024 Jul 3;68. doi: 10.29219/fnr.v68.10674. eCollection 2024.
Lung cancer, the most commonly diagnosed cancer globally, has the highest incidence and mortality rates in Taiwan. It can be divided into two types. Non-small cell lung cancer (NSCLC) accounts for approximately 85% of lung cancers, which is further divided into adenocarcinoma, squamous cell carcinoma, and large cell lung cancer accounting for approximately 40%, 25%, and 15% of NSCLC cases, respectively. Small cell lung cancer accounts for approximately 15% of lung cancers. Early systemic therapy NSCLC was based on chemotherapy, and immunotherapy is currently under development. Fucoidan, from brown seaweed extracts, shows promise in mitigating radiation-induced lung fibrosis in animal studies, suggesting its potential as an adjuvant for radiation therapy-related lung fibrosis in lung cancer patients. However, the clinical utility of such adjuvant therapy in lung cancer treatment remains uncertain. The purpose of this study was to investigate the effects of oral administration of oligo-fucoidan on the survival rate, quality of life, and immunity of patients with lung cancer.
Subjects with Non-small cell lung cancer aged between 20 and 80 were collected from outpatient clinics, divided into control group (n = 7): conventional therapy and fucoidan group (n = 13): received conventional therapy+ oral supplementation of oligo-fucoidan (550 mg × 4 tablets). Data were collected before the study, at weeks 4, 12, and 24 during the study, and to collect 20 ml of peripheral blood, for analysis biochemical data, liver and kidney function, lymphocyte population, inflammation cytokines, and using EORTC QLQ-C30 questionnaire to assess quality of life.
The survival rates of the subjects in the control and fucoidan groups were 20% and 28.6%, respectively. During the study, patients in the fucoidan group experienced a better quality of life than those in the control group, but this difference lacked statistical significance. Oligo-fucoidan increases the CD19 lymphocyte population. The patients in the fucoidan group also had Lower inflammatory cytokine.
Oligo-fucoidan holds promise as an adjuvant therapy to enhance the survival rate, quality of life, and immune function in patients with lung cancer.
肺癌是全球最常被诊断出的癌症，在台湾的发病率和死亡率最高。它可分为两种类型。非小细胞肺癌（NSCLC）约占肺癌的85%，进一步分为腺癌、鳞状细胞癌和大细胞肺癌，分别约占NSCLC病例的40%、25%和15%。小细胞肺癌约占肺癌的15%。早期非小细胞肺癌的全身治疗以化疗为主，免疫治疗目前正在研发中。岩藻多糖从褐藻提取物中提取，在动物研究中显示出减轻辐射诱导的肺纤维化的前景，表明其作为肺癌患者放疗相关肺纤维化辅助剂的潜力。然而，这种辅助治疗在肺癌治疗中的临床效用仍不确定。本研究的目的是调查口服低聚岩藻多糖对肺癌患者生存率、生活质量和免疫力的影响。
从门诊收集年龄在20至80岁之间的非小细胞肺癌患者，分为对照组（n = 7）：接受常规治疗；岩藻多糖组（n = 13）：接受常规治疗 + 口服补充低聚岩藻多糖（550毫克×4片）。在研究前、研究期间的第4周、第12周和第24周收集数据，并采集20毫升外周血，用于分析生化数据、肝肾功能、淋巴细胞群体、炎症细胞因子，并使用欧洲癌症研究与治疗组织QLQ-C30问卷评估生活质量。
对照组和岩藻多糖组患者的生存率分别为20%和28.6%。在研究期间，岩藻多糖组患者的生活质量比对照组患者更好，但这种差异缺乏统计学意义。低聚岩藻多糖增加了CD19淋巴细胞群体。岩藻多糖组患者的炎症细胞因子也较低。
低聚岩藻多糖有望作为一种辅助治疗方法，提高肺癌患者的生存率、生活质量和免疫功能。
